Similarly, sorafenib significantly decreased the expression of GPX4, and the expression of GPX4 in HCC cells of the si-TMEM39b + sorafenib group was even lower (Figs. 6I–6L). The gene discussed is TMEM39B; the disease is hepatocellular carcinoma.